Occurrence and number of immune-related adverse events are independently associated with survival in advanced non-small-cell lung cancer treated by nivolumab

L. Bouhlel, J. Doyen, Emmanuel Chamorey, M. Poudenx, Marius Ilié, Jocelyn Gal, J. Guigay, Jonathan Benzaquen, Charles‐Hugo Marquette, Jean‐Philippe Berthet, Jérôme Mouroux, Renaud Schiappa, B. Padovani, Paul Hofman, Josiane Otto